Roundtable Discussion: Contextualizing the Innovation in Novel ADC Tumor Biology & Enhanced ADC Targeting Design
- Understanding the level of innovation needed in bispecific ADC development to lead to differentiation against classical ADCs
- Forecasting translational considerations to set up novel target, bispecific, and antibody innovation-led innovation to success in the clinic
- Debating how antibody and alternative format ADC innovation will generate improved therapeutic profiles and patient impact versus novel payloads and mechanisms